Monoclonal antibody | |
---|---|
Type | ? |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
Monalizumab (formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies, and other cancers.
Monalizumab is a monoclonal antibody targeted at NKG2A. It is a checkpoint inhibitor.